Does CBL-514 really burn fat? Here's what we know
The primary endpoint of the 2025 Phase 2 CBL-514 trial was not weight loss, and it was not "fat burning." It was the proportion of participants who lost at least 150 mL of abdominal subcutaneous fat volume, measured by ultrasound. At 8 weeks after the final treatment, 69.6% (16/23) of CBL-514 participants hit that mark, versus 0% (0/16) on placebo (P < .001). The catch is that the denominators shrank over follow-up, the per-protocol group was only 30 people, and mean body weight did not fall.
Not medical advice. CBL-514 is investigational, not FDA-approved, and not a supplement.
What CBL-514 is (and isn't)
CBL-514 (not "CL-514") is an investigational small-molecule injectable from Caliway Biopharmaceuticals. Investigators inject it into subcutaneous fat, here the abdomen. It is not an oral pill or a consumer product. The papers do not disclose its chemical structure.
The proposed mechanism is injection lipolysis through targeted fat-cell (adipocyte) apoptosis. It is not a raised metabolic rate or calorie burning. Earlier nonclinical claims, including DYRK1b inhibition and caspase 3 and Bax/Bcl-2 upregulation, are cited to unpublished confidential company reports. The earlier Phase 2a study (Goodman et al., 2022) was smaller and open-label, not placebo-controlled.
The paper: Gold M, et al. Aesthet Surg J. 2025;45(6):611-620. Open access on PMC | PubMed | DOI | NCT04897412.
Design in brief
- Phase 2, randomized 2:1, single-blind (participants blinded; investigators and sponsor were not), placebo-controlled. Placebo was saline.
- Five centers in the US and Australia, February 2022 to March 2023.
- Up to 4 treatments at 4-week intervals, with follow-up 4 and 8 weeks after the last one. Each treatment used 25 to 50 injections of 2.4 mL (2 mg/cm²), up to 600 mg.
- Fat volume was calculated from ultrasound thickness at 4 points across a 300 cm² area.
- 76 were randomized (50 CBL-514, 26 placebo) and 75 were treated (49 and 26).
The headline numbers (ITT)
≥150 mL loss (primary endpoint)
| Follow-up | CBL-514 | Placebo | P |
|---|---|---|---|
| 4 weeks | 63.9% (23/36; 95% CI 46.22–79.18) | 17.4% (4/23; 95% CI 4.95–38.78) | <.001 |
| 8 weeks | 69.6% (16/23; 95% CI 47.08–86.79) | 0.0% (0/16) | <.001 |
≥200 mL loss
- 4 weeks: 58.3% (21/36) vs 8.7% (2/23), P < .001.
- 8 weeks: 60.9% (14/23) vs 0.0% (0/16), P < .001.
Exploratory ≥250 mL: 44.4% (16/36) at 4 weeks and 52.2% (12/23) at 8 weeks on CBL-514. No placebo participant reached it.
LS mean fat volume change vs baseline (CBL-514): −199.80 mL at 4 weeks and −209.46 mL at 8 weeks (both P < .001). The between-group differences were −206.62 mL (95% CI −276.09 to −137.16) and −216.28 mL (95% CI −288.28 to −144.28).
Per-protocol (n=30 only): −314.70 mL at 4 weeks and −279.45 mL at 8 weeks. Between-group differences were −312.08 mL and −276.83 mL. These are larger, but the PP set is small and selected for completers with stable weight.
The largest single loss was over 750 mL in one CBL-514 participant. That is a maximum, not a typical result.
Treatments to target: Of the 28 CBL-514 participants who reached ≥150 mL, 42.9% (12/28) did so after one treatment and 35.7% (10/28) after two, about 78.6% combined. In the PP group it was 44.4% (8/18) after one and 27.8% (5/18) after two.
The weight caveat
This is regional fat volume, not systemic fat oxidation. Mean body weight in the CBL-514 arm changed by +0.45 kg at 4 weeks and +0.02 kg at 8 weeks. Placebo changed by −0.76 kg and −0.26 kg. The authors report no significant change in mean weight or BMI, and say localized loss appeared even in some participants who gained more than 1 kg (data not shown). The data show a smaller treated abdomen, not a lighter body.
The denominator problem
Of 75 treated participants, 38 completed the study and 37 did not (49.3% non-completion). Reasons were:
- loss to follow-up (6)
- participant withdrawal (7)
- weight instability (7)
- schedule non-compliance (6)
- adverse events (4)
That is why the CBL-514 denominator falls from 36 to 23 and placebo from 23 to 16. The 8-week 0/16 placebo result is striking but rests on a small, shrinking group. Percentages at 8 weeks come from fewer people, with wide confidence intervals (for example 47.08–86.79% for the primary endpoint). The authors did not adjust for multiple testing, and the sample size was exploratory.
Photos and ultrasound: anecdotes
The paper shows two representative women, aged 49 and 46, with fat-volume reductions of 40.85%–47.37% and body-weight change under 1 kg. In the 46-year-old, ultrasound thickness at four points went from 4.06, 4.20, 3.90 and 3.26 cm at baseline to roughly 2 cm or less at both follow-ups. A 3D overlay suggested the loss stayed within the treated area. The authors saw little or no skin laxity in posttreatment images, but this was a visual impression, not a formal endpoint.
Safety: frequent, mostly local
Almost every participant had a treatment-related TEAE, at 98–100%, including the placebo group. Injection-site reactions drive the profile. The injection-site table highlights:
- Discoloration: 71.4% CBL-514 vs 11.5% placebo
- Induration: 61.2% vs 7.7%
- Severe pain: 18.4% vs 0%
The paper also reports severity breakdowns, pain medication use and resolution times, with most reactions resolving within about a week. Check the full text for exact figures. Two participants discontinued because of treatment-related events. One hyperlipidemia case was judged probably related. One serious event, peritoneal metastasis, was judged unrelated. No skin necrosis, ulceration or nerve injury was reported in this dataset.
How it compares (with caveats)
The authors cite cryolipolysis studies that used different measurement methods. One reported an average 264.8 mL abdomen and flank reduction at 12 weeks after up to 24 cycles over two sessions. Another reported 39.6 mL in the flank at 2 months after a single cycle. They say CBL-514's trend "appears to be larger," and call the results "comparable to that achieved with liposuction." These are the authors' interpretations. This trial included no head-to-head comparison with cryolipolysis or liposuction.
Limitations
- Phase 2 with short follow-up (8 weeks post-treatment)
- Single-blind design, with unblinded investigators
- Sponsor involvement in design, analysis, writing and the decision to publish
- High dropout and a small PP population
- Skewed demographics: 94.0% female in the CBL-514 arm, and 86.0% White
- Ultrasound volume derived from a cuboid formula, not a direct fat measurement
- No adjustment for multiple comparisons
Bottom line
CBL-514 reduced measured abdominal subcutaneous fat volume versus saline in this trial, with a large and statistically clear effect. It did not reduce body weight, and the evidence does not show systemic fat burning. Durability, larger confirmatory trials and independent replication are still needed, and the drug remains investigational.
More from this CBL-514 series
This article is part of our CBL-514 series. For the full Phase 2 trial overview, start here: CBL-514 Injection Lipolysis: A Phase 2 Map of the Evidence.